CDC's vaccine reporting VAERS has been shown to report only 1% of actual vaccine adverse events; now shows 1,268,008 adverse events, 28,141 deaths & 230,364 serious injuries Dec. 14, 2020-May 13, 2022
YET, despite this catastrophe of deaths and adverse events due to the COVID vaccine, CDC vaccine advisory panel follows FDA lead, endorses 3rd Pfizer shot for kids 5 to 11
“Adverse events from drugs and vaccines are common, but underreported. Although 25% of ambulatory patients experience an adverse drug event, less than 0.3% of all adverse drug events and 1-13% of serious events are reported to the Food and Drug Administration (FDA). Likewise, fewer than 1% of vaccine adverse events are reported.”
What is the new updates:
Well, ‘U.S. VAERS data from Dec. 14, 2020, to May 13, 2022, for 5- to 11-year-olds show:
22 reports of myocarditis and pericarditis (heart inflammation).The CDC uses a narrowed case definition of “myocarditis,” which excludes cases of cardiac arrest, ischemic strokes and deaths due to heart problems that occur before one has the chance to go to the emergency department.The Defender has noticed over previous weeks that reports of myocarditis and pericarditis have been removed by the CDC from the VAERS system in this age group. No explanation was provided.
43 reports of blood clotting disorders.
U.S. VAERS data from Dec. 14, 2020, to May 13, 2022, for 12- to 17-year-olds show:
168 reports of blood clotting disorders with all cases attributed to Pfizer.
U.S. VAERS data from Dec. 14, 2020, to May 13, 2022, for all age groups combined, show:
20% of deaths were related to cardiac disorders.
54% of those who died were male, 41% were female and the remaining death reports did not include the gender of the deceased.
The average age of death was 73.
2,291 reports of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
1,707 reports of myocardial infarction.
CDC vaccine advisory panel follows FDA lead, endorses 3rd Pfizer shot for kids 5 to 11
CDC Director Dr. Rochelle Walensky signed off on the Advisory Committee on Immunization Practices (ACIP) recommendation, clearing the way for healthcare workers to begin administering the shots.
The ACIP recommendation came two days after the FDA granted Pfizer’s request for Emergency Use Authorization (EUA) of a single booster dose for this age group, saying the third shot should be administered at least five months after the initial two-dose primary series with the Pfizer-BioNTech vaccine.’